Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 4 25 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 4 25 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 mL per day, infused at a rate not exceeding 2-3 mL/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
None Documented
None Documented
Not applicable as a single entity; components have variable half-lives: dextrose ~1-2h, amino acids ~1-3h for distribution, electrolytes vary. No terminal half-life defined.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Excretion depends on amino acid and electrolyte composition; nitrogen waste is eliminated renally as urea. Calcium and magnesium are primarily renally excreted; potassium is mostly renally eliminated. Dextrose is metabolized to CO2 and water. In renal impairment, accumulation may occur.
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution